Acellular Adipose Tissue (AAT)

Phase 2Biologic

JJohns Hopkins University

Acellular Adipose Tissue (AAT) is one of 6 biologic programs targeting ISS. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ISSEnrolling by invitation

ISSPhase 2

Enrolling by invitation

Competition

Competitive Landscape

8 competitors in ISS

#DrugCompanyPhaseTrials

Ginaton

PPeking University People's Hospital

Phase 3

1 2

Myrbetriq

Astellas

Phase 1

3 3

Methylprednisolone Hemisuccinate

BBBB-Therapeutics B.V.

Phase 3

1 4

Acellular Adipose Tissue (AAT)

JJohns Hopkins University

Phase 2

2 5

Reboxetine

UUniversity of Zurich

Preclinical

1 6

Psilocybine

UUniversity of Zurich

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

ISS2 trials

Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction

Enrolling by invitation·JJohns Hopkins University·Phase 2·NCT03544632·15 enrolled

Safety Study of Acellular Adipose Tissue for Soft Tissue Reconstruction

Completed·JJohns Hopkins University·Phase 1·NCT02817984·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Acellular Adipose Tissue (AAT). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acellular Adipose Tissue (AAT) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acellular Adipose Tissue (AAT). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: JJohns Hopkins University

Acellular Adipose Tissue (AAT)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

ISS2 trials

References

Drug Info

Quick Facts

Related News